A randomized, double-blind, multicenter phase III study to evaluate the long-term efficacy and safety of ABX464 25 mg or 50 mg once daily as a maintenance therapy in subjects with moderately to severely active ulcerative colitis. – ABTECT Maintenance - ABTECT Maintenance

Abivax SA0 个研究点目标入组 0 人开始时间: 待定最近更新: 2023年11月13日

研究概览

暂无简介。

•A subject will be eligible to participate in this study if ALL the following criteria are met:
•1. Subjects must have completed the induction treatment study (ABX464-105 or ABX464-106), and subjects’ clinical response status must be available.
•2. Subjects with a valid endoscopy performed at the end of the induction study and results from central reader available at Day 1.
•3. Subjects must understand, sign and date the written voluntary informed consent form at the visit prior to any protocol-specific procedures. For under-aged subjects, national requirements regarding consent should also be met.
•4. Women of childbearing potential (WOCBP) subjects and male subjects with WOCBP partner must agree to use highly effective contraception methods as stated in Section 4.4. (Contraception) of this protocol.
•5. Subjects must be able and willing to comply with study visits and procedures as per protocol.
•6. Subjects should be affiliated to a health insurance policy whenever required by a participating country or state.

•Subjects who meet ANY of the following exclusion criteria will be excluded from the study:
•1.Subjects who permanently discontinued the study treatment during the induction study (either ABX464-105 or ABX464-106).
•2.Subjects who plan to participate in other investigational studies during the maintenance study.
•3.Pregnant or breast-feeding women or male subject of a pregnant partner.
•4.Male or female subjects planning a pregnancy within the coming 12 months.
•5.Subjects who have not adhered to abstinence of prohibited and/or concomitant medications.
•6.Any changes in the laboratory values during the induction period that correspond with the following:
•Hemoglobin = 8.0 g dL-1
•Absolute neutrophil count < 750 mm-3
•Platelets < 100,000 mm-3
•Creatinine clearance < 60 mL.min-1 (Cockcroft-Gault formula)
•Total serum bilirubin > 1.5 x ULN
•Alkaline phosphatase, aspartate aminotransferase (AST) and alanine aminotransferase (ALT) > 2 x

发起方